Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥18 years of age~* Active rheumatoid arthritis of \>6 months duration~* Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline~Exclusion Criteria:~* Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis~* Major surgery within 8 weeks prior to screening or planned within 6 months following randomization~* Unsuccessful treatment with a biologic agent, including an anti-TNF agent~* Previous treatment with tocilizumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 8 mg/kg + DMARDs (Type: EXPERIMENTAL): None
- Placebo + DMARDs (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).